Study guide

4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential

Key Takeaways Explain This Topic AI

TA-TMA is an endothelial/complement-mediated syndrome after HCT that overlaps with infection, GVHD, drugs, relapse, DIC, TTP, and other causes of cytopenia or organ injury.

Harmonized clinical diagnosis requires at least four of seven features at two time points within 14 days: anemia, thrombocytopenia, LDH above ULN, schistocytes, hypertension, elevated sC5b-9, and rUPCR at least 1 mg/mg.

No single criterion is mandatory; haptoglobin, DAT, coagulation tests and ADAMTS13 support differential diagnosis but are not part of the seven-feature rule.

High-risk features include elevated sC5b-9, LDH at least 2 times ULN, rUPCR at least 1 mg/mg, multiorgan dysfunction, grade II-IV acute GVHD, or infection.

Severely deficient ADAMTS13 activity points to TTP rather than TA-TMA, while a consumptive coagulopathy with prolonged clotting times and low fibrinogen points to DIC, so these tests direct the differential rather than confirm TA-TMA.

Last updated: September 2026

Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Core Clinical Principle: TA-TMA is a multi-organ endothelial-injury syndrome after HCT. Rising LDH, anemia/thrombocytopenia, schistocytes, proteinuria, hypertension, and organ dysfunction should prompt serial evaluation and exclusion of mimics. ADAMTS13 and coagulation studies help distinguish TTP and DIC. Management addresses triggers and organ support; complement-directed drugs are used off-label in selected high-risk cases under specialist and institutional protocols, not as an automatic response to one laboratory finding.

1. Multi-Hit Pathophysiology & Complement Dysregulation

TA-TMA is not a single-agent disease; rather, it develops through a "multi-hit" cascade where underlying genetic host susceptibilities interact with sequential transplant-related toxicities to drive widespread microvascular endothelial destruction. +---------------------------------------------------------------------------------------------------+

  • | TA-TMA MULTI-HIT PATHOPHYSIOLOGY |
  • | |
  • | HIT 1: BASELINE SUSCEPTIBILITY |
  • | Underlying Complement Regulatory Gene Variants (CFH, CFI, CD46/MCP, C3, CFB) |
  • | | |
  • | v |
  • | HIT 2: CONDITIONING & INFLAMMATORY INSULTS |
  • | High-Dose TBI, Busulfan, Fludarabine + Sepsis + Viral Reactivations (CMV, HHV-6) + aGVHD |
  • | | |
  • | v |
  • | HIT 3: ENDOTHELIAL-TOXIC MEDICATIONS |
  • | Calcineurin Inhibitors (Tacrolimus, Cyclosporine) & mTOR Inhibitors (Sirolimus) |
  • | | |
  • | v |
  • | SYSTEMIC ENDOTHELIAL LYSIS & COMPLEMENT CASCADE ACTIVATION |
  • | * Subendothelial Exposure ---> Platelet Activation & Microvascular Fibrin-Platelet Thrombi |
  • | * Unchecked Alternative Complement Activation ---> Generation of C3a & C5a Anaphylatoxins |
  • | * Terminal Pathway Assembly: C5b + C6 + C7 + C8 + C9 ---> Soluble sC5b-9 (MAC Insertion) |
  • | | |
  • | v |
  • | MICROANGIOPATHIC HEMOLYSIS (MAHA) & MULTI-ORGAN ISCHEMIA |
  • | * RBC Mechanical Shearing across Microthrombi ---> Schistocytes, Anemia, High LDH, Low Haptoglobin|
  • | * Renal Microthrombosis ---> Proteinuria (rUPCR >= 1.0 mg/mg), Hypertension, AKI |
  • | * Neurologic, Intestinal & Pulmonary Microvascular Ischemic Necrosis |
  • +---------------------------------------------------------------------------------------------------+
  • The Role of the Complement Cascade in TA-TMA

Under normal physiological conditions, host regulatory proteins (Factor H, Factor I, Membrane Cofactor Protein / CD46, CD55, CD59) protect self-endothelial cells from alternative complement-mediated lysis. In TA-TMA:

Cumulative endothelial injury and loss of surface-bound protective complement regulators trigger uninhibited activation of the alternative complement pathway .

C3 Convertase and C5 Convertase cleave complement proteins into potent anaphylatoxins ( C3a and C5a ), which recruit neutrophils, induce severe vasoconstriction, and upregulate endothelial tissue factor.

C5 cleavage and terminal pathway: C5 convertase generates C5a and C5b; C5b binds C6, C7, C8 and C9 to form terminal complement complexes. Membrane-bound C5b-9 (the membrane attack complex) can injure endothelium.

Soluble biomarker: Plasma sC5b-9 is a soluble marker of terminal complement activation used in TA-TMA risk assessment. It is not the same as a membrane-inserting pore in the sampled plasma.

2. Harmonized Diagnostic Criteria & Clinical Manifestations

The international harmonization panel permits a clinical TA-TMA diagnosis when at least four of seven features occur at two time points within 14 days : anemia; thrombocytopenia; LDH above the upper limit of normal; schistocytes; hypertension (adult blood pressure at least 140/90 mm Hg, or pediatric value above the 99th percentile); soluble C5b-9 above the upper limit of normal; and random urine protein/creatinine ratio at least 1 mg/mg. No one feature—including schistocytes—is universally required.

Trend counts, smear, LDH, blood pressure, renal/proteinuria findings, complement marker when available, organ function, transfusion needs, and alternatives. Haptoglobin, bilirubin, reticulocytes, coagulation studies, direct antiglobulin testing, ADAMTS13, infection studies, medication review, and marrow/disease evaluation help the differential but are not all seven harmonized criteria. High-risk features include elevated sC5b-9, LDH at least twice the upper limit, rUPCR at least 1 mg/mg, multiorgan dysfunction, grade II–IV acute GVHD, or infection. Management addresses triggers and complications and uses specialist, protocol- or trial-directed complement therapy; automatically stopping a calcineurin inhibitor or applying one eculizumab schedule can be harmful.

Multi-Organ Manifestations of TA-TMA

Renal System: The kidneys are the primary target organ (>80% of cases). Manifests as acute kidney injury (AKI), severe oliguria, nephrotic-range proteinuria, and malignant hypertension.

Central Nervous System (CNS): Posterior Reversible Encephalopathy Syndrome (PRES), confusion, lethargy, severe intractable headaches, visual hallucinations, cortical blindness, focal neurological deficits, and status epilepticus.

Gastrointestinal System: Ischemic bowel necrosis, severe colicky abdominal pain, transmural ulcerations, gastrointestinal hemorrhage, and intestinal perforation (frequently misdiagnosed as refractory GI GVHD).

Cardiopulmonary System: Non-cardiogenic pulmonary edema, diffuse alveolar hemorrhage (DAH), pulmonary arterial hypertension, and pericardial effusions.

Loading diagram... TA-TMA Diagnostic Evaluation and Stepwise Management Flowsheet

3. Differential Diagnosis: TA-TMA, TTP, DIC and Immune Cytopenias

Feature TA-TMA Acquired TTP DIC Immune hemolysis/ITP

Context Endothelial injury after HCT with cytopenias/hemolysis and often hypertension, proteinuria or organ injury Severe ADAMTS13-deficiency syndrome with microangiopathic hemolysis and thrombocytopenia Triggered consumptive coagulation with bleeding/thrombosis Immune red-cell or platelet destruction; may be isolated

Coagulation/fibrinogen Often relatively preserved, but comorbidity can alter results Usually relatively preserved Often prolonged PT/PTT, high D-dimer and falling fibrinogen Usually preserved unless another process coexists

ADAMTS13 Severe deficiency is not typical Activity <10% strongly supports acquired TTP Not the defining abnormality Not the defining abnormality

DAT Usually negative; a positive result can indicate a concurrent process Usually negative Variable Can support immune hemolysis; ITP remains a clinical exclusion diagnosis

Management anchor Treat drivers/organ injury and use specialist-directed protocol or trial Urgent plasma exchange and TTP-directed therapy Treat cause and support coagulation Cause- and immune-directed therapy

Laboratory patterns overlap. A normal haptoglobin, absent schistocytes, or one coagulation result cannot independently exclude TA-TMA, and critically suspected TTP requires urgent escalation while ADAMTS13 testing is pending.

4. Screening in Practice: What to Measure and How Often

TA-TMA is missed because its early findings are individually unremarkable, and it is caught by scheduled screening rather than by clinical suspicion. Programs that detect it early screen prospectively during the highest-risk window rather than testing when a patient looks unwell.

Blood pressure is the most commonly overlooked element. Hypertension frequently precedes the laboratory abnormalities, and in pediatric patients it must be interpreted against age-, sex-, and height-based norms rather than a single adult threshold, so an elevated reading in a child can be dismissed by an adult-trained clinician.

Random urine protein-to-creatinine ratio is a simple, repeatable test that detects the renal endothelial injury early. Rising proteinuria in a patient with any hemolytic marker is a strong signal and correlates with worse outcomes.

Hemolysis markers - lactate dehydrogenase, haptoglobin, and the peripheral smear for schistocytes - are trended rather than read once, since the earliest change is often a rising LDH with a still-normal smear.

Transfusion requirement is an underused clue. A patient needing more red cells or platelets than the phase of transplant would predict, with no bleeding source, deserves TA-TMA evaluation.

Elevated soluble C5b-9 identifies higher-risk disease where it is available and helps distinguish patients who warrant closer follow-up.